Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
received:
07
01
2021
accepted:
21
09
2021
entrez:
16
10
2021
pubmed:
17
10
2021
medline:
29
1
2022
Statut:
epublish
Résumé
Accurate detection and risk stratification of latent tuberculosis infection (LTBI) remains a major clinical and public health problem. We hypothesize that multiparameter strategies that probe immune responses to Mycobacterium tuberculosis can provide new diagnostic insights into not only the status of LTBI infection, but also the risk of reactivation. After the initial proof-of-concept study, we developed a 13-plex immunoassay panel to profile cytokine release from peripheral blood mononuclear cells stimulated separately with Mtb-relevant and non-specific antigens to identify putative biomarker signatures. We sequentially enrolled 65 subjects with various risk of TB exposure, including 32 subjects with diagnosis of LTBI. Random Forest feature selection and statistical data reduction methods were applied to determine cytokine levels across different normalized stimulation conditions. Receiver Operator Characteristic (ROC) analysis for full and reduced feature sets revealed differences in biomarkers signatures for LTBI status and reactivation risk designations. The reduced set for increased risk included IP-10, IL-2, IFN-γ, TNF-α, IL-15, IL-17, CCL3, and CCL8 under varying normalized stimulation conditions. ROC curves determined predictive accuracies of > 80% for both LTBI diagnosis and increased risk designations. Our study findings suggest that a multiparameter diagnostic approach to detect normalized cytokine biomarker signatures might improve risk stratification in LTBI.
Identifiants
pubmed: 34654869
doi: 10.1038/s41598-021-99754-3
pii: 10.1038/s41598-021-99754-3
pmc: PMC8520014
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
20544Subventions
Organisme : NIAID NIH HHS
ID : R01 AI141591
Pays : United States
Organisme : NIAID NIH HHS
ID : AI141591
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
J Immunol. 2001 Jul 15;167(2):946-56
pubmed: 11441103
PLoS Pathog. 2016 Jul 13;12(7):e1005760
pubmed: 27409590
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
PLoS One. 2018 Aug 30;13(8):e0202736
pubmed: 30161159
Integr Biol (Camb). 2019 Jan 1;11(1):16-25
pubmed: 30722034
J Immunol. 2010 Apr 15;184(8):4414-22
pubmed: 20212094
Tuberculosis (Edinb). 2012 Nov;92(6):513-20
pubmed: 22824465
Clin Chim Acta. 2009 Aug;406(1-2):98-102
pubmed: 19523460
J Immunol. 2007 Apr 15;178(8):5217-26
pubmed: 17404305
Scand J Immunol. 2012 Dec;76(6):580-6
pubmed: 22946827
Eur Respir J. 2009 May;33(5):956-73
pubmed: 19407047
Lancet Infect Dis. 2012 Jan;12(1):45-55
pubmed: 21846592
Nat Rev Immunol. 2012 Jul 13;12(8):581-91
pubmed: 22790178
BMC Pulm Med. 2009 May 16;9:21
pubmed: 19445695
Nat Immunol. 2007 Apr;8(4):369-77
pubmed: 17351619
Nat Med. 2019 Jun;25(6):977-987
pubmed: 31110348
Tuberculosis (Edinb). 2018 Dec;113:30-37
pubmed: 30514511
Int J Tuberc Lung Dis. 2008 May;12(5):498-505
pubmed: 18419884
Curr Protoc Chem Biol. 2017 Sep 14;9(3):158-173
pubmed: 28910857
Nat Med. 2011 Mar;17(3):372-6
pubmed: 21336285
BMC Res Notes. 2009 Feb 04;2:19
pubmed: 19193208
PLoS One. 2011;6(11):e26545
pubmed: 22132075
J Immunol Methods. 2017 Sep;448:34-43
pubmed: 28527901
J Infect Dis. 2013 Apr 15;207(8):1253-61
pubmed: 23359591
Clin Infect Dis. 2017 Jan 15;64(2):111-115
pubmed: 28052967
Tuberculosis (Edinb). 2015 Jul;95(4):373-84
pubmed: 26038289
J Infect Dis. 2001 Feb 1;183(3):461-8
pubmed: 11133378
PLoS One. 2009 Dec 29;4(12):e8459
pubmed: 20041183
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130437
pubmed: 24821923
PLoS Pathog. 2018 May 21;14(5):e1007060
pubmed: 29782535
Sci Rep. 2019 Jun 3;9(1):8201
pubmed: 31160610
Int J Immunogenet. 2014 Apr;41(2):98-104
pubmed: 23998687
Am J Respir Crit Care Med. 2015 Sep 1;192(5):605-17
pubmed: 26030344
Sci Transl Med. 2020 Jan 29;12(528):
pubmed: 31996462